Evaluation of the cost of CA-125 measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer

Gynecologic Oncology

Volumn 131, Issue 3, 2013, Pages 503-507

  Armstrong, Amy ^a   Otvos, Balint ^b   Singh, Sareena ^a   Debernardo, Robert ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cost; Ovarian cancer; Surveillance

Indexed keywords

CA 125 ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MEDICARE; OVARY CANCER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REIMBURSEMENT; RETROSPECTIVE STUDY; UNITED STATES;

COST; OVARIAN CANCER; SURVEILLANCE;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; COST-BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; DISEASE-FREE SURVIVAL; FEMALE; HEALTH CARE COSTS; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; MODELS, ECONOMIC; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PHYSICAL EXAMINATION; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SEER PROGRAM; UNITED STATES;

EID: 84888298856     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.09.017     Document Type: Article

References (20)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Can J Clin 60 2010 277 300
2. A.N. Fader, and P.G. Rose Role of surgery in ovarian carcinoma J Clin Oncol 25 2007 2873 2883
3. P. Gu, L.L. Pan, S.Q. Wu, L. Sun, and G. Huang CA 125, PET alone, PET-CT, CT, and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis Eur J Radiol 71 2009 164 174
4. J.B. Trimbos, M. Parmar, and I. Vergote International collaborative ovarian neoplasm trial 1 and adjuvant chemo therapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early stage ovarian carcinoma J Natl Cancer Inst 95 2003 105 112
5. D.K. Armstrong, B. Bundy, and L. Wenzel Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43
6. A. Gadducci, E. Sartori, T. Maggino, P. Zola, F. Landoni, and A. Fanucchi Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study Gynecol Oncol 68 1998 150 155
7. J.S. Berek, C. Trope, and I. Vergote Surgery during chemotherapy and at relapse of ovarian cancer Ann Oncol 10 1999 3 7
8. T. Fehm, F. Heller, S. Kramer, W. Jager, and G. Gebauer Evaluation of CA 125, physical and radiological findings in follow-up of ovarian cancer patients Anticancer Res 25 2005 1551 1554
9. R.J. Morgan Jr., R.D. Alvarez, and D.L. Armstrong The NCCN ovarian cancer clinical practice guidelines in oncology J Natl Compr Cancer Netw 6 2008 766 794
10. B.A. Goff, L.S. Mandel, and C.W. Drescher Development of an ovarian cancer symptom index: possibilities for earlier detection Cancer 109 2 Jan 15 2007 221 227
11. R. von Georgi, K. Schubert, P. Grant, and K. Munstedt Post-therapy surveillance and after-care in ovarian cancer Eur J Obstet Gynecol Reprod Biol 114 2004 228 233
12. A. Gadducci, S. Cosio, P. Zola, F. Landoni, R. Maggino, and E. Sartori Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature Int J Gynecol Cancer 17 2007 21 31
13. G.J. Rustin, M.E. van der Burg on behalf of MRC and EORTC collaborators A randomized trial in ovarian cancer of early treatment of relapse based on CA 125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials) J Clin Oncol 27 2009 18s
14. E.J. Tanner, D.S. Chi, E.L. Eisenhauer, T.P. Diaz-Montes, A. Santillan, and R.E. Bristow Surveillance for recurrent ovarian cancer: survival impact or lead-time bias? Gynecol Oncol 117 2010 336 340
15. A. Gadducci, L. Fuso, and S. Cosio Are surveillance procedures of clinical benefit for patients treated for ovarian cancer? A retrospective Italian multicentric study Int J Gynecol Cancer 19 2009 367 374
16. SEER Stat Fact Sheets: Ovary. National Cancer Institute, Surveillance Epidemiology and End Results. www.cancer.gov.
17. E.A. Eisenhauer, J.B. Vermorken, and M. van Glabbeke Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients Ann Oncol 8 10 Oct 1997 963 968
18. M. Markman, B. Reichman, T. Hakes, W. Jones, J.L. Lewis Jr., and S. Rubin Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin J Clin Oncol 9 10 Oct 1991 1801 1805
19. C. Pisano, G.S. Bruni, G. Facchini, C. Marchetti, and S. Pignata Treatment of recurrent epithelial ovarian cancer Ther Clin Risk Manag 5 4 Aug 2009 421 426
20. S.M. Geurts, F. de Vegt, A.M. van Altena, J.A. van Dijck, V.C. Tjan-Heijnen, and A.L. Verbeek Considering early detection of relapsed ovarian cancer: a review of the literature Int J Gynecol Cancer 21 5 Jul 2011 837 845